Kangtai Bio kicks off clinical trial for enterovirus vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd., has initiated Phase I clinical trials for its quadrivalent inactivated enterovirus vaccine (Vero cells). The trial has successfully enrolled the first subject. The vaccine, administered via injection at a dosage of 0.5ml, is designed for individuals aged 6 months to 71 months susceptible to EV-A71, CV-A6, CV-A10, and CV-A16. The primary objective of the Phase I trial is to evaluate the safety and preliminary immunogenicity of the vaccine in healthy individuals aged 6 months and older. The company emphasized that the development and commercialization of vaccines are subject to various uncertainties.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shenzhen Kangtai Biological Products publishes news
Free account required • Unsubscribe anytime